Ad

ONC – Oncolytics Biotech Inc

Compliant

★★★★☆

Oncolytics Biotech Inc is Shariah compliant. The company’s financials pass four standards and fail in one.

$63,893,273

Market cap

-

Revenue Growth

BUY

Analysts' Rating

Ad

Recommendation Rating

1.75

1

2

3

4

5

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 5.78

Low: 4.71

High: 6.67

Total Analysts: 4

Company Profile

Oncolytics Biotech Inc. is a biotechnology company, which is engaged in developing pelareorep, an intravenously delivered immunotherapeutic agent. The Company is focused on the discovery and development of pharmaceutical products for the treatment of cancers. Its lead product, Pelareorep, is a systemically administered immuno-oncology (I-O) viral agent with the potential to treat a variety of cancers. Pelareorep’s anti-tumor activity is based on three modes: selective viral replication in permissive cancer cells, which leads to tumor cell lysis; activation of innate immunity in response to the infection, which results in a cascade of chemokines/cytokines, causing natural killer (NK) cells to be activated and attack cancer cells; and specific adaptive immune response triggered by tumor and viral-associated antigens displayed by antigen presenting cells (APCs), infected tumor cells and dendritic cells to T cells.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan

Ad

Responses